<DOC>
	<DOC>NCT00859287</DOC>
	<brief_summary>This open label, non-interventional study is to compare the efficacy of Omepral® tablet and any other treatments excepting proton pump inhibitors (PPIs) for the treatment of various type of acid reflux related symptoms in patients with reflux esophagitis.</brief_summary>
	<brief_title>Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis, Peptic</mesh_term>
	<criteria>Patients newly diagnosed as erosive esophagitis or history of erosive esophagitis confirmed by endoscopy. Patients who answered questionnaires of quality of life (QOLRADJ), symptom severity and frequency and treatment satisfaction. During the past 1 week , patients who have either two days or more with heartburn or acid taste in the mouth of any severity Patients receiving treatment with proton pump inhibitors, which make stomach acid decreased during the last 4 weeks prior to enrolment. Patients who cannot answer questionnaires of quality of life (QOLRADJ), symptom severity and frequency and treatment satisfaction. Patients included previously in this study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Reflux esophagitis</keyword>
	<keyword>Omepral®</keyword>
	<keyword>QOLRAD</keyword>
</DOC>